Half Yearly Report
Brisbane, Feb 19, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.
Highlights for the period include:
- APVMA approval and product application of Detach
- Steven Lydeamore appointed CEO
- Product Development Advisory Board established
- Progression of GaRP dietary supplement development program
To view the full report, please visit:
http://abnnewswire.net/lnk/V5527M9X
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
